LAPSES IN ASTHMA CONTROL IN PATIENTS WHO CONTINUED VS. DISCONTINUED OMALIZUMAB IN A REAL-WORLD SETTING.

被引：0
|
作者：
Sun, G.
Antonova, E.
Chang, E.
Broder, M.
Solari, P.
Zazzali, J.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2014年 / 113卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P80
引用
收藏
页码：A47 / A47
页数：1
相关论文
共 50 条
  • [21] Treatment patterns and outcomes among t(11;14) myeloma patients in a real-world setting.
    Norden, Andrew David
    Mathura, Shivam
    Hansen, Eric
    Goldberg, Stuart L.
    Siegel, David Samuel DiCapua
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma
    Buhl, Roland
    Korn, Stephanie
    Menzies-Gow, Andrew
    Aubier, Michel
    Chapman, Ken
    Canonica, Giorgio
    Picado, Cesar
    Donica, Margarita
    Button, Peter
    Kuhlbusch, Klaus
    Korom, Stephan
    Hanania, Nicola
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [23] COST-EFFECTIVENESS OF OMALIZUMAB IN SEVERE UNCONTROLLED ALLERGIC ASTHMA USING RCT AND REAL-WORLD EVIDENCE IN THE DUTCH SETTING
    Stern, S.
    van Nooten, F.
    Groot, M.
    Brown, R.
    VALUE IN HEALTH, 2011, 14 (07) : A493 - A493
  • [24] Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma
    Kavati, Abhishek
    Zhdanava, Maryia
    Ortiz, Benjamin
    Lecocq, Jason
    Schiffman, Bradd
    Pilon, Dominic
    Ho, Harriet
    Lefebvre, Patrick
    Stone, Brian
    CLINICAL THERAPEUTICS, 2019, 41 (10) : 1956 - 1971
  • [25] Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic
    Kirchnerova, Olga Ruzickova
    Valena, Tomas
    Novosad, Jakub
    Terl, Milan
    Bystron, J.
    Chlumsky, J.
    Kindlova, D.
    Klosova, J.
    Krcmova, I
    Parakova, Z.
    Pohunek, P.
    Popelkova, P.
    Sedlak, V
    Vanik, P.
    Vernerova, E.
    Zatloukal, J.
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2019, 36 (01): : 34 - 43
  • [26] Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab
    Ke, Xuehua
    Kavati, Abhishek
    Wertz, Debra
    Huang, Qing
    Wang, Liya
    Willey, Vincent J.
    Stephenson, Judith J.
    Ortiz, Benjamin
    Panettieri, Reynold A., Jr.
    Corren, Jonathan
    CLINICAL THERAPEUTICS, 2018, 40 (07) : 1140 - 1158
  • [27] Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
    Casale, Thomas B.
    Luskin, Allan T.
    Busse, William
    Zeiger, Robert S.
    Trzaskoma, Benjamin
    Yang, Ming
    Griffin, Noelle M.
    Chipps, Bradley E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (01): : 156 - +
  • [28] Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
    Barthwal, Madhusudan
    Dutta, Vijay
    Bhattacharya, Parthasarthi
    Vora, Agam
    Kotnis, Mangala
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [29] Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
    Lee, Jason K.
    Amin, Suvina
    Erdmann, Michelle
    Kukaswadia, Atif
    Ivanovic, Jelena
    Fischer, Aren
    Gendron, Alain
    PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 725 - 735
  • [30] Comparative Glycemic Effectiveness of Dulaglutide vs. Liraglutide and Exenatide QW in a US Real-World Setting
    Mody, Reema
    Huang, Qing
    Yu, Maria
    Patel, Hiren
    Zhao, Ruizhi
    Grabner, Michael
    Lando, Laura Fernandez
    DIABETES, 2018, 67
12345